Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deflazacort

FDA-approved product (tablet, oral), marketed as Deflazacort, Emflaza, Jaythari and 1 more.

Registered studies
24
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Deflazacort
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duchenne muscular dystrophy
  • Muscular dystrophy
  • Qualitative or quantitative defects of dysferlin

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Glucocorticoids
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deflazacort in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deflazacort with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

    NCT02295748 · start 2014-12

    Registered record
    Registry ID
    NCT02295748
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2017-08-24
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionDeflazacort
    PhasePhase 1
    Registry statusCompleted

  • Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

    NCT02286635 · start 2014-11

    Registered record
    Registry ID
    NCT02286635
    Conditions
    Healthy Volunteers
    Interventions
    Deflazacort and rifampin; Deflazacort and Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    2014-12
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionDeflazacort and rifampin; Deflazacort and Clarithromycin
    PhasePhase 1
    Registry statusCompleted

  • Heart Rate Variability in Individuals With Duchenne Muscular Dystrophy

    NCT04740554 · start 2013-03-01

    Registered record
    Registry ID
    NCT04740554
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Duchenne Muscular Dystrophy group with Deflazacort; Duchenne Muscular Dystrophy group with Prednisone/Predisolone; Duchenne Muscular Dystrophy group without Corticosteroids therapy; Control Group Typically Developing
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03-01
    Completion
    2015-02-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionDuchenne Muscular Dystrophy group with Deflazacort; Duchenne Muscular Dystrophy group with Prednisone/Predisolone; Duchenne Muscular Dystrophy group without Corticosteroids therapy; Control Group Typically Developing
    PhaseNot recorded
    Registry statusCompleted

  • Finding the Optimum Regimen for Duchenne Muscular Dystrophy

    NCT01603407 · start 2013-01

    Registered record
    Registry ID
    NCT01603407
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Prednisone; Prednisone; Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2019-11
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionPrednisone; Prednisone; Deflazacort
    PhasePhase 3
    Registry statusCompleted

  • Kidney Graft Function Under the Immunosuppression Strategies

    NCT01817322 · start 2011-06

    Registered record
    Registry ID
    NCT01817322
    Conditions
    Chronic Renal Disease
    Interventions
    Standard Dose of Myfortic and Reduced Dose of Myfortic; Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group; Basiliximab injected both control group and experimental group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-06
    Completion
    2013-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Renal Disease
    InterventionStandard Dose of Myfortic and Reduced Dose of Myfortic; Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group; Basiliximab injected both control group and experimental group
    PhasePhase 4
    Registry statusCompleted

  • Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

    NCT01282073 · start 2011-03

    Registered record
    Registry ID
    NCT01282073
    Conditions
    Glomerulonephritis, Membranous
    Interventions
    Mycophenolate mofetil, low dose steroid; Cyclosporin, low dose steroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2016-05
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlomerulonephritis, Membranous
    InterventionMycophenolate mofetil, low dose steroid; Cyclosporin, low dose steroid
    PhasePhase 3
    Registry statusCompleted

  • Biomechanical Analysis of Gait in Individuals With Duchenne Muscular Dystrophy

    NCT00312247 · start 2006-04

    Registered record
    Registry ID
    NCT00312247
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-04
    Completion
    2015-03
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Deflazacort in Dysferlinopathies

    NCT00527228 · start 2003-09

    Registered record
    Registry ID
    NCT00527228
    Conditions
    LGMD2B; Miyoshi Myopathy; Dysferlinopathy
    Interventions
    deflazacort; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2003-09
    Completion
    2008-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLGMD2B; Miyoshi Myopathy; Dysferlinopathy
    Interventiondeflazacort; placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

    NCT02592941

    Registered record
    Registry ID
    NCT02592941
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Deflazacort
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionDeflazacort
    PhaseNot recorded
    Registry statusApproved for marketing